Rocket Pharmaceuticals, Inc. Costs and Expenses, Related Party
Rocket Pharmaceuticals, Inc. (RCKT) reported Costs and Expenses, Related Party of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpensesRelatedParty · last filed 2026-02-26
- Rocket Pharmaceuticals, Inc. costs and expenses, related party for the quarter ending 2025-09-30 was $0.00.
- Rocket Pharmaceuticals, Inc. costs and expenses, related party for the quarter ending 2025-06-30 was $0.00.
- Rocket Pharmaceuticals, Inc. costs and expenses, related party for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. costs and expenses, related party for the quarter ending 2024-12-31 was -$2.00M.
- Rocket Pharmaceuticals, Inc. costs and expenses, related party for fiscal 2024 was $2.00K, a 90.00% decline from fiscal 2023.
- Rocket Pharmaceuticals, Inc. costs and expenses, related party for fiscal 2023 was $20.00K.
| Period end | Costs and Expenses, Related Party 3 month | Costs and Expenses, Related Party 3 month as first filed | Costs and Expenses, Related Party 6 month | Costs and Expenses, Related Party 6 month as first filed | Costs and Expenses, Related Party 9 month | Costs and Expenses, Related Party 9 month as first filed | Costs and Expenses, Related Party 12 month |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$2.00M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | -$2.00M derived: sum of 3 quarters · filed 2026-02-26 | -$2.00M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | -$2.00M derived: sum of 2 quarters · filed 2026-02-26 | -$2.00M derived: sum of 3 quarters · filed 2026-02-26 | -$2.00M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.00M derived: sum of 2 quarters · filed 2026-02-26 | -$2.00M derived: sum of 3 quarters · filed 2026-02-26 | $2.00K 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $2.00M 10-Q · filed 2025-11-06 | $2.00K 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.00M 10-Q · filed 2025-08-07 | $2.00K 10-Q · filed 2024-08-06 | ||||
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-08 | $2.00K 10-Q · filed 2024-05-07 | |||||
| 2023-12-31 | $20.00K 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |